Propranolol and the hypercalcaemia of thyrotoxicosis.
The effect of propranolol on serum calcium was studied in 25 patients with thyrotoxicosis including 5 with hypercalcemia. In patients with hypercalcaemia iv propranolol significantly reduced serum calcium. Oral therapy 160 mg/day reduced calcium non-significantly from 2.72 +/- 0.09 (mean +/- SD) to 2.59 +/- 0.13 mmol/l, however on 320 mg/day the reduction (to 2.5 +/- 0.15 mmol/l) was significant. In normocalcaemic patients oral propranolol did not influence serum calcium. Both in hyper- and normocalcemic thyrotoxic patients propranolol increased (P less than 0.01) serum phosphate.
D000293:Adolescent; D000328:Adult; D000368:Aged; D002118:Calcium / Q000097:blood*; D005260:Female; D006801:Humans; D006934:Hypercalcemia / Q000150:complications; D006980:Hyperthyroidism / Q000097:blood* / Q000150:complications; D008297:Male; D008875:Middle Aged; D010710:Phosphates / Q000097:blood; D011433:Propranolol / Q000494:pharmacology*; D013963:Thyroid Hormones / Q000097:blood
D010710:Phosphates; D013963:Thyroid Hormones; D011433:Propranolol; D002118:Calcium